INDP Indaptus Therapeutics: מכפיל P/S עתידי

The strategic vector of Indaptus Therapeutics (INDP) is focused on creating cancer treatment methods that are resilient to macro shocks. The business's forward P/S demonstrates progress on this path, where captures a new level. The complexity of utilizing killed bacteria in therapy serves as an obstacle; however, experienced management effectively controls cash flow, ensuring the stability of current clinical trials.

The effectiveness of Indaptus Therapeutics (INDP) immunotherapy is limited by geopolitical barriers that slow global drug registration and constrain revenue growth. The ratio of market capitalization to projected sales volume allows for a real-time assessment of market expectations regarding asset monetization, while the future P/S multiple serves as an indicator of the company's overvaluation amid regulatory risks and stagnant clinical trials.